Vertaling van "products is coming from " (Nederlands → Frans) :

Growth across the Galvus group of products is coming from launches in France, Japan, Korea and Turkey, as well as ongoing strong performance in Europe, notably in Germany, Spain, Greece and Portugal.
La croissance de l’ensemble du groupe de produits Galvus provient des lancements en France, au Japon, en Corée du Sud et en Turquie, ainsi que de la poursuite de la vigoureuse croissance en Europe, notamment en Allemagne, en Espagne, en Grèce et au Portugal.

The analysis of the FAMHP’s own income shows that 60% of it comes from fees for service and 40% from taxes.
The analysis of the FAMHP’s own income shows that 60% of it comes from fees for service and 40% from taxes.

Free cash flow before dividends rose 93% to USD 2.9 billion, with the USD 1.4 billion increase principally coming from the improved cash flow from operating activities.
Le free cash flow avant dividendes a fait un bond de 93% à USD 2,9 milliards, la hausse d'USD 1,4 milliard provenant essentiellement de l’amélioration des flux de trésorerie issus des activités opérationnelles.

Free cash flow before dividends rose 34% to USD 8.2 billion, the increase principally coming from the improved cash flow from operating activities.
Le free cash flow avant dividendes a fait un bond de 34% à USD 8,2 milliards, grâce essentiellement à l’amélioration des flux de trésorerie provenant des activités opérationnelles.

Zometa (USD 363 million, -3% cc) volume expansion offset by negative EU and Japanese pricing, continued to come from improved compliance and increased use of this intravenous bisphosphonate therapy in patients with certain types of cancer which have spread to the bone.
Zometa (USD 363 millions, -3% tcc), expansion en volume contrebalancée par une fixation défavorable des prix par l’UE et le Japon, progresse grâce à une amélioration de sa conformité et à une augmentation de l’utilisation de ce traitement intraveineux au bisphosphonate contre certains types de cancers provoquant des métastases osseuses.

Zometa (USD 378 million, +6% cc) expansion has come from improved compliance and increased use of this intravenous bisphosphonate therapy in patients with certain types of cancer which have spread to the bone.
Zometa (USD 378 millions, +6% tcc), progresse grâce à une amélioration de sa conformité et à une augmentation de l’utilisation de ce traitement intraveineux au bisphosphonate contre certains types de cancers provoquant des métastases osseuses.

Zometa (USD 375 million, +5% cc) expansion has come from improved compliance and use of this intravenous bisphosphonate therapy in patients with certain types of cancer that has spread to bones, particularly in key European markets.
Zometa (USD 375 millions, +5% tcc), traitement au bisphosphonate intraveineux contre les métastases osseuses du cancer, progresse grâce à une amélioration de sa conformité et de son utilisation, particulièrement dans les principaux marchés européens.

All regions continued to benefit from the product portfolio rejuvenation, particularly Europe (USD 2.7 billion, +8% cc), generating 27% of its net sales from recently launched products.
Toutes les régions ont continué de bénéficier du rajeunissement du portefeuille de produits, en particulier l’Europe (USD 2,7 milliards, +8% tcc) dont 27% du chiffre d’affaires net proviennent de ces nouveaux produits.

The cases dealt with in these meetings may be complaints by consumers or producers, requests for advice from inspection services, formal opinions on the formulation of regulations, formal opinions for companies wishing to market products and to ensure that they are presenting their product correctly, and internal cases that serve for the compilation of guidelines for the consultation platform.
The cases dealt with in these meetings may be complaints by consumers or producers, requests for advice from inspection services, formal opinions on the formulation of regulations, formal opinions for companies wishing to market products and to ensure that they are presenting their product correctly, and internal cases that serve for the compilation of guidelines for the consultation platform.

The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.
The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.